Toviaz — Blue Cross Blue Shield of Kansas
Treatment of neurogenic detrusor overactivity (NDO) in pediatric patients as labeled
Preferred products
- darifenacin
- oxybutynin chloride
- trospium chloride
- tolterodine tartrate
Initial criteria
- Step therapy applies: patient must have tried and failed or have contraindication to preferred urinary incontinence agents prior to approval of non-preferred agents.